Navigation Links
Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
Date:10/27/2009

CALGARY, Oct. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 33rd U.S. Patent, # 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus." The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

"This patent supports our expanding clinical program, including our first Phase III study, looking at REOLYSIN(R) in combination with a range of chemotherapeutic agents," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "Many of our studies enroll patients that did not previously respond to chemotherapy, including our Phase III study in patients with platinum refractory head and neck cancers."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in th
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
2. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
3. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
5. Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
6. Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology
7. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
8. Epeius Biotechnologies to Partner at BIO Investor Forum
9. Reportlinker Adds Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis
10. Sosei Announces Deal With UK Biotech Company
11. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2
... COLOGNE, Germany and BANGALORE, India , ... laboratory worldwide in Electronics City in,the Indian city of ... in independent safety and quality testing for solar modules has,invested ... which in particular will,offer services to India,s growing ...
... Aug. 4 Amplimmune, Inc. today announced that it has ... PD-1 targeting therapies that may be effective in the treatment of cancer ... well as other potential next generation fusion proteins that target PD-1.   ... Under the ...
... 3 K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that ... ("BDO") as the Company,s independent registered accounting firm. , ... The Company and BDO will commence work immediately on ... will then follow with the review of its quarterly filings for fiscal year ...
Cached Biology Technology:New Test Centre in India: TUV Rheinland Continues Worldwide Investment Programme for Solar Industry 2New Test Centre in India: TUV Rheinland Continues Worldwide Investment Programme for Solar Industry 3GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration 2GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration 3K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 2K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 3K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 4K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 5K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 6K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 7K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants 8
(Date:8/21/2014)... of American singles found that during sex with ... rates. On average, men experience orgasm 85.1 percent ... little difference. For women, however, orgasm occurrence is ... percent of the time during sex with a ... women,s sexual orientation, with lesbian women experiencing orgasm ...
(Date:8/21/2014)... fungus linked to dandruff, eczema and other itchy, flaky ... further global reachesincluding Hawaiian coral reefs and the extreme ... A review in the scientific journal PLOS Pathogens ... fungi of the genus Malassezia in light ... from around the world. , University of Hawai,i at ...
(Date:8/21/2014)... In a finding that has implications for life in ... in the solar system, LSU Associate Professor of Biological ... National Science Foundation, or NSF, this week published a ... lake that lies 800 meters (2600 feet) beneath the ... microbial ecosystems.", Given that more than 400 subglacial lakes ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4
... new technique for turning embryonic stem cells into insulin-producing ... in the quest to find new treatments for diabetes. ... at the University of Sheffield, were able to genetically ... important protein known as a transcription factor. Stem ...
... camps atop glaciers in some of the most remote regions ... Branch at NASA,s Goddard Space Flight Center in Greenbelt, Md., ... Striking images taken by NASA satellites offer further visual evidence ... at the ends of the Earth. On Thursday, April ...
... Davis shows how our very short-term "working memory," which allows ... retains a limited number of high-resolution images for a few ... Humans rarely move their eyes smoothly. As our eyes flit ... to cut down visual "noise," said Steven J. Luck, professor ...
Cached Biology News:Stem cell breakthrough offers diabetes hope 2NASA expert to address Earth's vanishing polar ice, April 10, at UD 2Working memory has limited 'slots' 2